Real-world safety and effectiveness of mepolizumab for patients with eosinophilic granulomatosis with polyangiitis in Japan: A 48-week interim analysis of the MARS study.

Tomonori IshiiHideaki KunishigeTamami KobayashiEtsuko HayashiMasaki KomatsubaraTakeo IshiiRafael Alfonso-CristanchoJun TamaokiPeter Howarth

Published in: Modern rheumatology (2024)

The results of mepolizumab treatment for ≥144 weeks (before baseline plus observation) were consistent with the known safety profile and allowed OCS dose reduction while improving disease control versus pre-treatment among patients with EGPA.

Keyphrases

randomized controlled trial
clinical trial
replacement therapy
study protocol
preterm birth
gestational age
smoking cessation